Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405816 | 0.86 | ADORA2A (0.50) | ADORA2AADORA1 | |
| SCHEMBL5413238 | 0.86 | ADORA2A (0.60) | ADORA2AADORA1DRD2DRD4DRD3 | |
| SCHEMBL5426661 | 0.85 | ADORA2A (0.51) | ADORA2AADORA1 | |
| SCHEMBL5405896 | 0.85 | ADORA2A (0.52) | ADORA2AADORA1 | |
| SCHEMBL5418811 | 0.84 | ADORA2A (0.55) | ADORA2AADORA1DRD2DRD4DRD3 | |
| SCHEMBL5413540 | 0.83 | ADORA2A (0.53) | ADORA2AADORA1DRD2DRD4DRD3 | |
| SCHEMBL5413520 | 0.82 | ADORA2A (0.49) | ADORA2AADORA1 | |
| SCHEMBL5417198 | 0.80 | ADORA2A (0.77) | ADORA2AADORA1 | |
| SCHEMBL5420831 | 0.80 | ADORA2A (0.51) | ADORA2AADORA1 | |
| SCHEMBL5421674 | 0.80 | ADORA2A (0.51) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285550-B2 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-12-07 | — | — | US | claimed |
| EP-1615930-A2 | TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA, Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092170-A2 | TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGON ISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885DRD2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.